Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 4/20 | 0.58 |
| ▸ | MLNR | O43193 | 1/20 | 0.58 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.58 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.58 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.58 |
| ▸ | DRD2 | P14416 | 1/20 | 0.58 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.58 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.58 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.58 |
| ▸ | CNR1 | P21554 | 1/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.58 |
| ▸ | NPY1R | P25929 | 1/20 | 0.58 |
| ▸ | HTR2A | P28223 | 1/20 | 0.58 |
| ▸ | HTR2C | P28335 | 1/20 | 0.58 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20007025 | 1.00 | HTR1A (0.58) | HTR1AMLNRADRB2ADRB1ADRA2A | |
| SCHEMBL935303 | 1.00 | HTR1A (0.58) | HTR1AMLNRADRB2ADRB1ADRA2A | |
| Hydrochloric Acid SCHEMBL16340249 | 0.98 | HTR1A (0.57) | HTR1AMLNRADRB2ADRB1ADRA2A | |
| Hydrochloric Acid SCHEMBL2248981 | 0.98 | HTR1A (0.57) | HTR1AMLNRADRB2ADRB1ADRA2A | |
| Formic Acid SCHEMBL28804070 | 0.93 | HTR1A (0.55) | HTR1AMLNRADRB2ADRB1ADRA2A | |
| SCHEMBL6856918 | 0.88 | HTR1A (0.52) | HTR1AMLNRADRB2ADRB1ADRA2A | |
| SCHEMBL14681243 | 0.88 | HTR1A (0.52) | HTR1AMLNRADRB2ADRB1ADRA2A | |
| SCHEMBL6856896 | 0.88 | HTR1A (0.52) | HTR1AMLNRADRB2ADRB1ADRA2A | |
| SCHEMBL1041687 | 0.87 | DRD2 (0.45) | HTR1AMLNRADRB2ADRB1ADRA2A | |
| SCHEMBL4932628 | 0.85 | HTR1A (0.52) | HTR1AMLNRADRB2ADRB1ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119413926-B | Method for detecting propyl ketone impurity in nebivolol hydrochloride starting material | 济南立德医药技术有限公司 | 2025-03-28 | — | — | CN | claimed |
| CN-119413926-A | Method for detecting propyl ketone impurity in nebivolol hydrochloride starting material | 济南立德医药技术有限公司 | 2025-02-11 | — | — | CN | claimed |
| CN-118010886-A | Method for detecting dichloro impurities in nebivolol hydrochloride bulk drug | 济南立德医药技术有限公司 | 2024-05-10 | — | — | CN | claimed |
| CN-119413926-B | Method for detecting propyl ketone impurity in nebivolol hydrochloride starting material | 济南立德医药技术有限公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-119413926-A | Method for detecting propyl ketone impurity in nebivolol hydrochloride starting material | 济南立德医药技术有限公司 | 2025-02-11 | — | — | CN | disclosed |
| CN-118373795-A | Continuous flow preparation process of chloroketone | 济南立德医药技术有限公司 | 2024-07-23 | — | — | CN | disclosed |
| CN-118373795-A | Continuous flow preparation process of chloroketone | 济南立德医药技术有限公司 | 2024-07-23 | — | — | CN | disclosed |
| CN-118010886-A | Method for detecting dichloro impurities in nebivolol hydrochloride bulk drug | 济南立德医药技术有限公司 | 2024-05-10 | — | — | CN | disclosed |
| CN-118010886-A | Method for detecting dichloro impurities in nebivolol hydrochloride bulk drug | 济南立德医药技术有限公司 | 2024-05-10 | — | — | CN | disclosed |
| CN-110305099-B | Preparation and application of nebivolol-based Smo inhibitor | 东南大学 | 2022-11-29 | — | — | CN | disclosed |
| CN-106317006-A | Preparation method of 6-fluorochromane-2-formaldehyde as nebivolol intermediate | 陕西思尔生物科技有限公司 | 2017-01-11 | — | — | CN | disclosed |
| US-7560575-B2 | Process for preparation of racemic Nebivolol | ACINO PHARMA AG (CH) | 2009-07-14 | — | — | US | disclosed |
| US-7560575-B2 | Process for preparation of racemic Nebivolol | ACINO PHARMA AG (CH) | 2009-07-14 | — | — | US | disclosed |
| US-20090048457-A1 | PROCESS FOR PREPARATION OF RACEMIC NEBIVOLOL | CIMEX PHARMA AG (CH) | 2009-02-19 | — | — | US | disclosed |
| US-20090048457-A1 | PROCESS FOR PREPARATION OF RACEMIC NEBIVOLOL | CIMEX PHARMA AG (CH) | 2009-02-19 | — | — | US | disclosed |
| WO-2008040528-A2 | PROCESS FOR PREPARING NEBIVOLOL | ZACH SYSTEM S.P.A. (IT) | 2008-04-10 | — | — | WO | disclosed |
| WO-2008010022-A2 | A PROCESS FOR PREPARATION OF RACEMIC NEBIVOLOL | CIMEX PHARMA AG (US) | 2008-01-24 | — | — | WO | disclosed |
| US-20070149612-A1 | Process for preparation of racemic Nebivolol | ACINO PHARMA AG (CH) | 2007-06-28 | — | — | US | disclosed |
| US-20070149612-A1 | Process for preparation of racemic Nebivolol | ACINO PHARMA AG (CH) | 2007-06-28 | — | — | US | disclosed |
| US-5824682-A | Vasoconstrictive dihydrobenzopyran derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 1998-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048457-A1 | PROCESS FOR PREPARATION OF RACEMIC NEBIVOLOL | ADRB1, ADRB2, ADRA2B | HTR1A 101/4885MLNR 452/4885ADRB2 2/4885 |
| US-20070149612-A1 | Process for preparation of racemic Nebivolol | ADRB1, ADRB2, ADRA2B | HTR1A 101/4885MLNR 452/4885ADRB2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.